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ABSTRACT
Objective To evaluate a multistrain, high-dose
probiotic in the prevention of eczema.
Design A randomised, double-blind, placebo-
controlled, parallel group trial.
Settings Antenatal clinics, research clinic, children at
home.
Patients Pregnant women and their infants.
Interventions Women from 36 weeks gestation and
their infants to age 6 months received daily either the
probiotic (Lactobacillus salivarius CUL61, Lactobacillus
paracasei CUL08, Biﬁdobacterium animalis subspecies
lactis CUL34 and Biﬁdobacterium biﬁdum CUL20; total
of 1010 organisms/day) or matching placebo.
Main outcome measure Diagnosed eczema at age
2 years. Infants were followed up by questionnaire.
Clinical examination and skin prick tests to common
allergens were done at 6 months and 2 years.
Results The cumulative frequency of diagnosed eczema
at 2 years was similar in the probiotic (73/214, 34.1%)
and placebo arms (72/222, 32.4%; OR 1.07, 95% CI
0.72 to 1.6). Among the secondary outcomes, the
cumulative frequency of skin prick sensitivity at 2 years
was reduced in the probiotic (18/171; 10.5%) compared
with the placebo arm (32/173; 18.5%; OR 0.52, 95%
CI 0.28 to 0.98). The statistically signiﬁcant differences
between the arms were mainly in sensitisation to cow’s
milk and hen’s egg proteins at 6 months. Atopic eczema
occurred in 9/171 (5.3%) children in the probiotic arm
and 21/173 (12.1%) in the placebo arm (OR 0.40, 95%
CI 0.18 to 0.91).
Conclusions The study did not provide evidence that
the probiotic either prevented eczema during the study
or reduced its severity. However, the probiotic seemed to
prevent atopic sensitisation to common food allergens
and so reduce the incidence of atopic eczema in early
childhood.
Trial registration Number ISRCTN26287422.
INTRODUCTION
The major atopic disorders, eczema, allergic rhinitis
and asthma, cause signiﬁcant disease burdens
worldwide. Symptoms of atopy were reported to
occur in 15–40% of children aged 13–14 years
living in the UK in the mid-1990s1 and prevalence
has increased in many countries in recent years.2–4
Despite the high atopic disease burden, patho-
genic mechanisms remain poorly understood.
Atopic disorders are heterogeneous resulting from
complex interactions between environmental
factors, including exposure to microbes, and host
genes modulating innate and acquired immune
responses, and mucosal and skin integrity.5 A crit-
ical issue is the role of atopy deﬁned as a genetic
propensity to develop immunoglobulin E anti-
bodies following exposure to allergens6 and
assessed by skin prick tests (SPTs) or measurement
of speciﬁc IgE in serum. For eczema7 and asthma,8
atopic sensitisation early in life has been associated
with persistent disease.
The hygiene hypothesis, based on the observation
of increased atopy in smaller families,9 postulates
that reduced exposure to infections in early child-
hood results in aberrant immunological responses to
allergens.10 Intestinal microbiota provide a critical
source of early immune stimulation and variations
in early gut colonisation have been associated with
the development of atopic disease.11 Probiotics are
deﬁned as live microorganisms which, when admi-
nistered in adequate amounts, confer health beneﬁts
on the host.12 However, the term ‘probiotic’ is com-
monly used for microorganisms that are undergoing
evaluation for possible health beneﬁts and it is this
sense that is used here. Clinical trials suggest a role
for probiotics in the primary prevention of atopic
eczema.13 The mechanisms whereby probiotics may
prevent atopy are unclear but might involve reduced
exposure to allergens through improved epithelial
barrier function and modulation of the developing
immune system to prevent IgE sensitisation.14
We evaluated the effect of a probiotic comprising
two strains of lactobacilli and two strains of biﬁdo-
bacteria, or an inert placebo, administered to
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▸ Skin prick sensitivity to common food allergens
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mother-infant dyads in the perinatal period on clinical and
laboratory manifestations of atopy. Here, we report the clinical
manifestations of atopy at age 0–2 years.
METHODS
The safety proﬁle of the probiotic15 and factors determining
compliance with the trial procedures16 have been published.
Participants
Women aged 16 years or more, with a normal singleton preg-
nancy and intending to give birth at Singleton Hospital,
Swansea were invited to join the study. Details of the recruit-
ment process are described elsewhere.16 Women with known
adverse conditions likely to affect them, the fetus, or the
outcome of the pregnancy, were excluded. Women were
informed of the trial, by letter, at booking, and provided with
further information when attending for antenatal care. Those
returning an expression of interest were contacted by research-
ers. Signed, informed consent was obtained by a researcher at
35–36 weeks gestation.
We had intended to recruit infants at ‘high-risk’ of developing
atopy deﬁned as those with a ﬁrst degree relative with either
asthma or eczema diagnosed by a health professional or allergic
rhinitis treated by a doctor.17 However, sufﬁcient details of
atopy in ﬁrst degree relatives were often difﬁcult to obtain at
recruitment. Therefore, in practice, infants with and without an
increased risk of atopy were recruited. To preserve the integrity
of the random allocation sequence, all infants are included in
this report. Key ﬁndings relating to those at increased risk of
atopy are presented in Webtable 1.
Randomisation
Pregnant women were allocated on a 1:1 basis at 36 weeks ges-
tation to either the active or placebo arm of the study according
to a computer-generated, random sequence without blocks. The
random sequence was generated by the commercial partners and
held independently of the research team. Women were allocated
consecutively to the next number in the randomisation sequence
and provided with the corresponding, preprepared intervention
pack.
Intervention
We selected a multispecies probiotic preparation on the basis of
greater efﬁcacy than either single species or single organism pre-
parations in the prevention or treatment of diseases in animal
models and clinical trials.18 Species that had been evaluated in
previous clinical trials, including the prevention of eczema were
selected.17 Organisms were selected on the basis of activity in
promoting responses in vitro consistent with protection against
allergy (personal communication; Dr S. Plummer 2003).
The active intervention comprised a vegetarian capsule con-
taining Lactobacillus salivarius CUL61 (National Collection of
Industrial, Food and Marine Bacteria (NCIMB) 30211)
6.25×109 colony forming units (CFUs), Lactobacillus paracasei
CUL08 (NCIMB 30154) 1.25×109 CFUs, Biﬁdobacterium
animalis subspecies lactis CUL34 (NCIMB 30172) 1.25×109
CFUs and Biﬁdobacterium biﬁdum CUL20 (NCIMB 30153)
1.25×109 CFUs as a freeze-dried powder. Organism identity
was conﬁrmed at the species and strain levels by 16S rRNA
gene sequencing, rep PCR ﬁngerprinting and cluster analysis,
and Random Ampliﬁed Polymorphic DNA typing. Women in
the placebo arm received capsules of identical appearance con-
taining maltodextrin powder. The dose in both arms was one
capsule daily from 36 weeks gestation until delivery. Infants
received the same capsules as their mother once daily from birth
to age 6 months. Women were asked to store the capsules in the
fridge and either took the capsule by mouth or sprinkled the
contents onto food. The contents of the capsule were sprinkled
directly into the infant’s open mouth or mixed with expressed
breast milk or formula feed. Mothers were asked not to
consume any commercially available probiotics or live yoghurts
or administer these to their infants.
Unused capsules returned by participants from intervention
and placebo groups for compliance monitoring were tested by
an independent laboratory on an opportunistic basis. No live
bacteria were identiﬁed in the placebo capsules, conforming
with the random allocation sequence. Viability of the bacteria in
the active preparation was consistent with the storage conditions
conﬁrming no signiﬁcant deterioration in the product.
Data collection and allergen testing
Demographic information and possible risk factors for atopy
were recorded at recruitment. Follow-up questionnaires were
scheduled every 6 weeks to age 6 months and at 1 year and
2 years. A research assistant completed questionnaires with the
parent/carer during a home visit at age 6 weeks, during research
clinics at 6 months and 2 years and by telephone interview at
other times. Where a follow-up was missed, parents/carers were
asked to provide information for the period since the last ques-
tionnaire was completed. Questionnaires recorded any atopic
disorders diagnosed by health professionals, treatments received
and the occurrence and duration of common skin, respiratory
and gastrointestinal symptoms.
At research clinics, infants were examined by either a clinician
or a trained researcher. If present, the severity of eczema was
evaluated by the scoring atopic dermatitis index.19 SPTs using
common food allergens (cow’s milk, hen’s egg), aeroallergens
(house dust mite, cat dander, grass pollen) and positive (hista-
mine) and negative controls were performed. The response to
an allergen was considered positive if there was a wheal diam-
eter ≥3 mm.20
Outcome measures
The primary outcome was the cumulative frequency of diag-
nosed eczema at 2 year follow-up (reported by parents/carers to
have been diagnosed by a health professional or diagnosed
during a research clinic). Eczema was deﬁned as an itchy rash
affecting the face, scalp or extensor surfaces of the limbs in
infants and ﬂexures in older children and of duration ≥4 weeks
and with ≥1 exacerbation by age 24 months21 based on the
information from questionnaires. Secondary outcomes were
responses to SPTs, atopic eczema deﬁned as eczema with one or
more positive SPTs, eczema of any duration and whether or not
diagnosed by a health professional, the severity of eczema, treat-
ment with topical steroid preparations, respiratory symptoms
with asthma and allergic rhinitis and reported food allergy. We
had intended to report outcomes up to age 2 years. However,
scheduled follow-up assessments were often delayed particularly
when mothers had returned to work. Therefore, we have
included all information for children aged up to, but not includ-
ing, 3 years.
Data management and analysis
Strict blinding of the clinical research teams regarding partici-
pant allocation was maintained until after databases were locked
following completion of data collection. The period of
follow-up, deﬁned as the time from birth to the age of the last
follow-up questionnaire, was calculated for each infant.
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Demographic variables, possible risk factors for atopy, and
primary and secondary outcomes were analysed by treatment
allocated. Findings for binary outcomes were expressed in ORs
with 95% CIs. A χ2 test or Fisher’s exact test was used to
compare proportions. Continuous outcome variables had
skewed distributions and were summarised using median values
and IQR and compared by the Mann-Whitney U test.
We performed adjusted analyses to investigate whether the
trends in atopic sensitivity or atopic eczema were modiﬁed by
baseline demographic variables (table 1), possible risk factors
for atopy (table 2) and mother and infant compliance. For com-
pliance, participants were classiﬁed as no compliance and com-
pliance levels 1–4 representing the quartiles of the total number
of days that trial interventions were taken. We used a set of
logistic regression models, including the study treatment in each
case and adding the other variables in a stepwise manner, retain-
ing them in the model if they resulted in a signiﬁcant improve-
ment in model ﬁt (at the 5% level). Analysis was performed
using R/SPSS V.16.0 (IBM, USA)/SAS V.9·2 (SAS Institute, USA).
Sample size
We aimed to recruit sufﬁcient mother/infant dyads to observe a
50% reduction in the frequency of asthma by age 5 years from
20% to 10%.22 For the purposes of this paper, we expected
that 40% of infants at increased risk of atopy (deﬁned as having
a ﬁrst degree relative with an atopic condition) in the placebo
arm would have developed eczema by age 2 years.17 23 A total
of 308 infants (154 in each arm) would be sufﬁcient to detect a
50% reduction in eczema frequency from 40% in the control
arm to 20% in the probiotic arm with 90% power at the 1%
signiﬁcance level.
Role of the funding source
Cultech UK advised on study design, provided the trial interven-
tions and generated the random allocation sequence but was not
involved in data collection, analysis or interpretation of the
ﬁndings.
Ethics approval
The study was approved by the local research ethics committee
in February 2004 and registered with Current Controlled Trials
(ISRCTN26287422).
RESULTS
Participants
Recruitment began in May 2005 and the last scheduled 2 year
contact was in November 2009. Of 1419 women attending
antenatal clinics who had expressed an interest in the study, 454
were recruited and randomised (ﬁgure 1; Trial proﬁle).
Demographic variables and possible risk factors for atopy
were similar in the 220 women randomised to the probiotic
Table 2 Potential modulating factors for atopy during follow-up
Variable Probiotic arm Placebo arm
Breast fed (full or partial)—any duration 49/191 (25.7%) 47/205 (22.9%)
Age last breast fed in months (N;
median, (IQR))
185; 1 [0–7] 190; 1 [0–5]
Attended child-minder in first 12 months 10/163 (6.1%) 16/172 (9.3%)
Attended nursery in first 12 months 65/162 (40.1%) 61/170 (35.9%)
Any oral/systemic antibiotics 155/214 (72.4%) 154/225 (68.4%)
This table gives the number of participants (%) unless otherwise stated.
Figure 1 Trial proﬁle *Reasons for exclusion: pregnancy complication
(n=110); presented after 36 weeks gestation or at the end of the
recruitment period and before 36 weeks gestation (83); multiple
pregnancy (14); contacted again after recruitment terminated (9);
previous infant participated in trial (6); unwilling to stop current
probiotic (1). †Reasons for failure to participate: lost contact with
research team (288); not sufﬁciently interested or disliked tests (184);
concern that trial was “too much to take on” (129); unwillingness to
take the investigation products (85); not prepared to be allocated to
the placebo arm (21); developed a medical condition (16); language
difﬁculties (10); not willing for this child to be treated differently from
previous child (7); bereavement (2). ‡Follow-up was often delayed;
includes children seen up to, but not including, age 3 years.
Table 1 Demographic characteristics and possible risk factors for
atopy at baseline
Variable Probiotic arm* Placebo arm*
Socioeconomic status (Townsend
rank; N; median, IQR)
220; 949 (333–1514) 234; 864 (330–1558)
Mother smoked during
pregnancy
41/205 (20.0%) 47/218 (21.6%)
Vaginal delivery 152/216 (70.4%) 157/232 (67.7%)
House
Cat, dog, rodent or bird kept
indoors
112/220 (50.9%) 120/234 (51.3%)
Damp and/or mould as
reported by participants
59/217 (27.2%) 56/232 (24.1%)
No. households with
1 adult 10/220 (4.6%) 9/234 (3.9%)
≥3 adults 20/220 (9.1%) 25/234 (10.7%)
no other children 81/220 (36.8%) 93/234 (39.7%)
≥3 other children 16/220 (7.3%) 18/234 (7.7%)
No. infants at increased risk of
atopy†
197/220 (89.6%) 205/234 (87.6%)
This table gives the number of participants (%) unless otherwise stated.
*Denominator varies according to information provided by parents/carers and
compliance with follow-up.
†Defined as first degree relative with either asthma or eczema diagnosed by a health
professional or allergic rhinitis treated by a doctor.
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arm and 234 to the placebo arm (table 1). Maternal smoking
during pregnancy, keeping pets and houses affected by damp or
mould were common in both arms. Three hundred and seventy-
four women were carrying an infant at high risk of developing
atopy with a similar proportion in each study arm (table 1).
Potential modifying factors for atopy during follow-up, such as
feeding practice, exposure to other people and to antibiotics,
were also similar in the two arms (table 2).
Completion of questionnaires and attendance at research
clinics was similar in the two arms (ﬁgure 1). Median (IQR) age
at follow-up was 2.11 years (2.01–2.28 years) in the probiotic
arm and 2.09 years (2.01–2.24 years) in the placebo arm
(p=0.28). We have reported previously that follow-up was
more complete among less deprived families and mothers who
were non-smokers.
The trial arm was not associated with retention or clinic
attendance at 24 weeks and 2 years.16
Primary outcome measure
The cumulative frequency of diagnosed eczema (a composite of
carers’ reports and research clinic ﬁndings) at 2 years was
similar in the probiotic (73/214; 34.1%) and placebo arms
(72/222, 32.4%; OR 1.07, 95% CI 0.72 to 1.6; p=0.71).
Secondary outcome measures
Positive SPTs to one or more common allergens at either age
6 months or 2 years were signiﬁcantly less frequent in the pro-
biotic arm (OR 0.52, 0.28–0.98; p=0.036, table 3). The
number needed to treat to prevent one infant becoming sensi-
tised was 13 (95% CI 7 to 173). The reduced skin prick
responses in the probiotic arm were mainly to food allergens
(cow’s milk and egg proteins) and statistically signiﬁcant differ-
ences were already apparent at age 6 months. In contrast, sensi-
tisation to aeroallergens (house dust mite, cat dander and grass
pollen) occurred mainly after 6 months and was similar in the
two arms (table 3).
Atopic eczema at 2 years was signiﬁcantly less frequent in the
probiotic arm (OR 0.40, 0.18–0.91; p=0.024) and was appar-
ent by age 6 months (table 3). Differences between the two
groups in non-SPT positive eczema were not statistically signiﬁ-
cant. At age 6 months, non-SPT positive eczema occurred in 37/
147 (25.2%) children in the probiotic and 24/143 (16.8%) in
the placebo arm (χ2=3.06; p=0.08). At age 2 years, non-SPT
positive eczema occurred in 57/171 (33.3%) children in the pro-
biotic and 46/173 (26.6%) in the placebo arm (χ2=1.86;
p=0.17). The cumulative frequency of all eczema to age 2 years
reported by parents and carers, whether or not diagnosed by a
Table 3 Secondary outcomes according to intervention group
Variable Probiotic arm Placebo arm OR (95% CI) p Value*
SPT† positive at 6 m 6/151 (3.97%) 16/147 (10.88%) 0.34 (0.13 to 0.89) 0.023
▸ cow’s milk 0/148 (0.0%) 5/147 (3.40%) – 0.030*
▸ egg 5/148 (3.4%) 14/147 (9.5%) 0.33 (0.11 to 0.95) 0.032
▸ house dust mite 1/151 (0.66%) 0/147 (0.0%) – 0.51*
▸ cat 0/151 (0.0%) 2/145 (1.4%) – 0.24*
▸ grass 1/150 (0.67%) 0/147 (0.0%) – 0.49*
SPT† positive at either 6 m or 2 yrs 18/171 (10.5%) 32/173 (18.5%) 0.52 (0.28 to 0.98) 0.036
▸ cow’s milk 1/171 (0.6%) 6/173 (3.5%) 0.16 (0.02 to 1.4) 0.12*
▸ egg 9/171 (5.3%) 19/173 (11.0%) 0.45 (0.2 to 1.0) 0.052
▸ house dust mite 9/171 (5.3%) 11/173 (6.4%) 0.82 (0.3 to 2.0) 0.66
▸ cat 3/171 (1.8%) 7/173 (4.0%) 0.42 (0.1 to 1.7) 0.20
▸ grass 2/171 (1.2%) 2/173 (1.2%) 1.0 (0.14 to 7.2) 0.99*
Skin
▸ Atopic eczema at 6 m 4/151 (2.7%) 13/147 (8.8%) 0.28 (0.089 to 0.88) 0.021
▸ Severity of eczema at 6 m clinic‡; median, (IQR) 14.3 (7.5–17.9) 14.4 (10.6–24.9) – 0.46
▸ Atopic eczema at 2 yrs 9/171 (5.3%) 21/173 (12.1%) 0.40 (0.18 to 0.91) 0.024
▸ Severity of eczema at 2 yr clinic‡; median (IQR) 11.1 (7.2–20.1) 14.2 (7.2–14.2) – 0.85
▸ All reported eczema§,¶ 119/214 (55.6%) 132/226 (58.4%) 0.90 (0.61 to 1.3) 0.55
▸ Received topical steroid preparation 30/214 (14.0%) 40/226 (17.7%) 0.76 (0.45 to 1.2) 0.29
Respiratory
▸ All reported asthma¶ 23/171 (11.9%) 20/179 (10.0%) 1.2 (0.63 to 2.3) 0.57
▸ Night-time cough 156/214 (72.9%) 164/226 (72.6%) 1.0 (0.67 to 1.5) 0.93
▸ Night-time or daytime cough 178/214 (83.2%) 188/226 (83.2%) 1.0 (0.6 to 1.6) 0.99
▸ Wheezing without symptoms of a virus infection 50/214 (23.4%) 55/171 (24.3%) 0.95 (0.61 to 1.47) 0.81
▸ Inhaled bronchodilator or steroid 26/214 (12.1%) 27/226 (11.9%) 1.0 (0.57 to 1.8) 0.94
▸ Allergic rhinitis¶ 10/190 (5.3%) 10/201 (5.0%) 1.1 (0.43 to 2.6) 0.90
▸ Sneezing and/or snuffling 207/214 (96.7%) 212/226 (93.8%) 1.95 (0.77 to 4.93) 0.15
Any reported food allergy 22/200 (11.0%) 31/204 (15.2%) 0.69 (0.38 to 1.2) 0.21
This table gives the number of participants (%) unless otherwise stated.
*χ2 test for contingency tables or Fisher’s exact test* where expected values in cells were <5.
†SPT valid if diameter of wheal for the positive control was ≥1 mm than diameter for the negative control; SPT positive if diameter of wheal for antigen was ≥3 mm than diameter for
negative control.
‡SCORAD index19.
§Of any duration.
¶Whether or not diagnosed by a health professional.
SCORAD, scoring atopic dermatitis; SPT, skin prick test.
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health professional, its severity, the duration of rash and the use
of topical steroids were similar in the two arms. The cumulative
frequency of asthma and allergic rhinitis and symptoms and
treatments consistent with these conditions and of reported
food allergy were also similar in both arms (table 3).
The differences between the two arms in the risk of atopic
eczema and SPT positivity among infants with one or more rela-
tives with atopy were very similar to those in the whole cohort
(webtable 1). However, with the exception of reduced sensitivity
to cow’s milk protein at 6 months, differences in the smaller
cohort did not reach statistical signiﬁcance. Median (IQR) com-
pliance with the trial interventions in pregnant women was 20
(12–28) days in the probiotic arm and 20 (12–28) days in the
placebo arm (p=0.98, Mann-Whitney U test). In infants, the
corresponding values were 106 (30–141) days and 103 (11–
151) days (p=0.97, Mann-Whitney U test). In logistic regression
analyses, in almost all cases, additional variables (table 1) were
not signiﬁcantly related to clinical outcomes and did not change
the estimated OR for the effect of the probiotic. The exception
was the presence of a smoker in the household; this was a sig-
niﬁcant risk factor for atopic eczema and atopic sensitivity (OR
at 2 years: 2.48, 95% CI 1.08 to 5.70; p=0.033 and OR 2.25,
95% CI 1.16 to 4.37; p=0.017 respectively). This effect was
independent of the treatment and did not signiﬁcantly modify
the univariate OR for the treatment effect. There was no evi-
dence for an interaction effect between smoking and treatment
allocation.
We have reported previously that probiotic administration
was not associated with adverse effects in either mothers or
their infants.15
DISCUSSION
Our ﬁndings do not support the administration of a multistrain,
high-dose probiotic to mothers during late pregnancy and their
infants from birth to age 6 months for the prevention of eczema
in early childhood. However, probiotic administration was asso-
ciated with a reduced frequency in sensitivity to food antigens
and atopic eczema.
The strengths of our study are the relatively large number of
mother-infant dyads recruited, the pragmatic nature of the trial,
and conﬁrmation of identity and viability of the probiotic
organisms.
The study had several weaknesses. We had intended to evalu-
ate clinical outcomes in infants at increased risk of atopy identi-
ﬁed by having one or more ﬁrst degree relatives with atopy. In
practice, this was difﬁcult to determine accurately at recruit-
ment. However, the frequency of atopy and effects of the pro-
biotic were similar in infants with and without a ﬁrst degree
relative with atopy. We expected that administering a novel
intervention to healthy young infants would be difﬁcult and,
although compliance with the trial interventions in mothers was
good, compliance was lower in infants. Finally, many mothers
returned to work and this resulted in missed or delayed
follow-up questionnaires and study clinic attendances. Although
we compensated for missed follow-ups by subsequently asking
parents and carers for information since the last assessment was
done, this may have resulted in some loss of accuracy of
information.
Our ﬁnding that the study probiotic did not affect the fre-
quency of eczema is inconsistent with a meta-analysis of 13 ran-
domised, placebo-controlled trials (3092 infants/children),
where probiotic administration was associated with modest
reductions in the frequency of eczema (ﬁxed effects analysis;
RR 0.79; 95% CI 0.71 to 0.88).24 Despite agreement between
studies in the meta-analysis (I2=24.0%),24 variability in out-
comes between studies are likely to result from differences in
the probiotics used,25 the contribution of atopic and other
pathogenic factors including variations in host mucosal and skin
integrity,5 26 the diagnostic criteria, and outcome measures used
for eczema.27
Our observations of reduced frequency of skin prick sensitiv-
ity to food allergens and eczema in children with demonstrated
allergic sensitivity in the probiotic arm are consistent with those
of a meta-analysis (20 cohorts; 4031 participants, including our
ﬁndings) where probiotic administration during infancy and
childhood was associated with reduced serum IgE and atopic
sensitisation to food or inhalant allergens in random effects ana-
lysis with limited heterogeneity between studies and without
evidence of publication bias.28
In our study, in contrast to food allergens, sensitivity to aeroal-
lergens was similar in the two arms. This tends to develop after
infancy29 and, with the exception of two studies,30 31 most
researchers have also reported that probiotic administration during
early infancy did not reduce aeroallergen sensitivity.25 32–39 Our
observation that probiotic administration did not reduce the fre-
quency of asthma or wheeze in young children is consistent with
other studies.28
CONCLUSION
Administration of probiotics in early life may have a role in the
prevention of atopic sensitisation. However, a better under-
standing of strain-speciﬁc probiotic effects25 40 and how these
address underlying atopic mechanisms is needed to guide the
selection of strains for evaluation in clinical trials. Long-term
follow-up to determine the effect of probiotic administration on
the allergic march is also a priority.41
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